MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
May 9, 2022
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain
April 5, 2022
MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices The availability of larger quantities …
Expanded Access Study Site in California Begins Screening
March 22, 2022
Our Expanded Access Program study site at Sage Integrative Health in Berkeley, California, began screening participants for MDMA-assisted therapy for PTSD in early March. Our multi-site expanded access …
Participant Experiences & “Cover Story”
March 1, 2022
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
Results for Phase 1 Randomized Controlled Trial of MDMA and Fear Extinction Retention in Healthy Adults Published in Psychopharmacology
February 15, 2022
On February 15, 2022, the results of our evaluation of MDMA on the startle response in healthy adults was published in the medical journal Psychopharmacology. This randomized, blinded, placebo-controlled …
Results for Phase 1 Randomized Controlled Trial of MDMA and Fear Extinction Retention in Healthy Adults Published in Psychopharmacology
February 15, 2022
On February 15, 2022, the results of the MAPS-sponsored study by Barbara Rothbaum and team at Emory University evaluating MDMA on the startle response in healthy adults was published in the medical journal …
Ten Phone Screenings Conducted in Expanded Access Study for MDMA-Assisted Therapy for PTSD
February 5, 2022
Our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was activated for phone …
Phone Screenings Open and Site Initiation Visits Conducted at Study Sites for Expanded Access Program for MDMA-Assisted Therapy for PTSD
January 24, 2022
On December 10, 2021, our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was …
Psyche Unbound, a collection of essays in honor of Stanislav Grof, to be released in January 2022
December 8, 2021
Psyche Unbound: Essays in Honor of Stanislav Grof is an extraordinary compilation of twenty-two essays that honor the path-breaking lifework of Stanislav Grof, M.D., Ph.D., the world’s leading researcher …
MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million
December 2, 2021
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
May 11, 2021
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
MDMA-Assisted Therapy for PTSD in couples may reduce PTSD symptoms and improve couples’ happiness
December 8, 2020
A Phase 1/2 open-label treatment development study of MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in dyads in which one member has chronic posttraumatic stress disorder (PTSD) shows MDMA-Assisted …